Compare MFA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | ACRS |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.0M | 868.5M |
| IPO Year | 1998 | 2015 |
| Metric | MFA | ACRS |
|---|---|---|
| Price | $9.15 | $5.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $11.05 | $10.20 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 14.16% | N/A |
| EPS Growth | 58.54 | ★ 69.01 |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.02 | $4.24 |
| P/E Ratio | $39.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.80 | $1.70 |
| 52 Week High | $10.57 | $6.52 |
| Indicator | MFA | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 57.90 |
| Support Level | $8.90 | $4.13 |
| Resistance Level | $9.38 | $6.52 |
| Average True Range (ATR) | 0.17 | 0.37 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 67.37 | 59.47 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets; and Lima One.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.